GlassScriptPhysician profile
Jefferson C Jones
NPI 1700063336
$1,472.18
in general payments reported to CMS, 2019-2025
23 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $211 · 2021: $41.48 · 2022: $173 · 2023: $249 · 2024: $342 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $890.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $515.59 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $111.95 | 2019-2022 | |
| Hologic Sales and Service, LLC | $91.75 | 2019-2020 | |
| Abbvie INC. | $87.37 | 2019-2025 | |
| Biogen, INC. | $77.22 | 2025 | Zurzuvae |
| Pfizer INC. | $76.39 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $72.60 | 2024-2025 | |
| Inspire Medical Systems, INC. | $60.12 | 2024 | Inspire |
| Organon LLC | $43.59 | 2023-2025 | Nexplanon |
| Baxter Healthcare | $43.27 | 2022-2024 | Tisseel, Perclot |
| Sumitomo Pharma America, INC. | $37.73 | 2023 | Myfembree |
| Glaxosmithkline, LLC. | $35.49 | 2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Minerva Surgical, INC | $35.01 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.18 | 2025 | |
| Optumhealth Care Solutions, LLC | $28.92 | 2024 | Eitan Medical, Vivify Health Care Team Portal 001 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $24.00 | 2019 | |
| Roche Diagnostics Corporation | $16.74 | 2019 | |
| Coopersurgical, INC. | $16.11 | 2023 | Summit Doppler |
| Lilly USA, LLC | $13.63 | 2024 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.62 | 2025 | Caplyta |
| Amag Pharmaceuticals, INC. | $13.60 | 2019 | |
| Myovant Sciences INC. | $12.47 | 2022 | |
| Meditrina | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jefferson Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.